首页 | 本学科首页   官方微博 | 高级检索  
     

全脑放疗联合靶向治疗与同步放、化疗治疗非小细胞肺癌脑转移的临床疗效
引用本文:岳顺,张大红,袁颖. 全脑放疗联合靶向治疗与同步放、化疗治疗非小细胞肺癌脑转移的临床疗效[J]. 安徽医药, 2017, 21(1): 123-126. DOI: 10.3969/j.issn.1009-6469.2017.01.033
作者姓名:岳顺  张大红  袁颖
作者单位:淮安市第一人民医院肿瘤内科,江苏淮安,223300;淮安市第一人民医院肿瘤内科,江苏淮安,223300;淮安市第一人民医院肿瘤内科,江苏淮安,223300
摘    要:目的 对比分析全脑放疗联合靶向治疗与同步放、化疗治疗非小细胞肺癌(NSCLC)脑转移的临床疗效及安全性.方法选取NSCLC脑转移病人56例作为研究的对象,经随机数字表法将之分为联合组与放化疗组,联合组病人采取全脑放疗联合靶向药物治疗,放化疗组采取全脑放疗以及同步化疗治疗.对病人进行为期2年的随访,比较两组病人治疗6个月后的临床疗效,并观察病人治疗期间并发症的发生情况以及随访期间的生存情况.结果联合组的脑转移病灶、总体评价的治疗有效率(RR)、疾病控制率(DCR)均显著高于放化疗组(P<0.05);联合组骨髓抑制、消化道反应的发生率均显著低于放化疗组,而皮疹脱屑的发病率则高于放化疗组(P<0.05);联合组1年生存率显著高于放化疗组,且平均生存时间较放化疗组更长(P<0.05);治疗结束后,联合组生存质量上升者显著多于放化疗组,而生存质量下降者则显著少于放化疗组(P<0.05).结论全脑放疗联合靶向治疗应用于NSCLC脑转移病人具有较好的疗效,能够减少不良反应,延长病人的生存时间.

关 键 词:非小细胞肺癌  脑转移  靶向治疗  化疗  放疗
收稿时间:2016-07-29
修稿时间:2016-11-24

Clinical effect of whole brain radiotherapy combined with targeted therapy and synchronous radiotherapy and chemotherapy in the treatment of non-small cell lung cancer with brain metastasis
YUE Shun,ZHANG Dahong and YUAN Ying. Clinical effect of whole brain radiotherapy combined with targeted therapy and synchronous radiotherapy and chemotherapy in the treatment of non-small cell lung cancer with brain metastasis[J]. Anhui Medical and Pharmaceutical Journal, 2017, 21(1): 123-126. DOI: 10.3969/j.issn.1009-6469.2017.01.033
Authors:YUE Shun  ZHANG Dahong  YUAN Ying
Affiliation:Department of Oncology,Huai''an First People''s Hospital,Huai''an,Jiangsu 223300,China,Department of Oncology,Huai''an First People''s Hospital,Huai''an,Jiangsu 223300,China and Department of Oncology,Huai''an First People''s Hospital,Huai''an,Jiangsu 223300,China
Abstract:Objective To compare the clinical efficacy and safety of whole brain radiotherapy combined with targeted therapy and syn-chronous radiotherapy and chemotherapy in the treatment of non-small cell lung cancer (NSCLC)with brain metastases.Methods Fifty six cases of NSCLC patients with brain metastasis were selected as the research object,and divided into combined group and chem-otherapy group according to the random number table method.The patients of the combination group were treated with whole brain radio-therapy combined with target to drug treatment,while radiotherapy and chemotherapy group were treated with whole brain radiotherapy and concurrent chemotherapy treatment.Patients were followed up for 2 years.The clinical efficacy of 2 groups of patients after 6 month-sof treatment were compared,and the incidence of complications during treatment and the survival of patients during follow up were ob-served.Results Brain metastasis lesions,the overall evaluation of the RR,DCR in combined group were significantly higher than that of the chemoradiotherapy group (P<0.05).The bone marrow suppression,gastrointestinal reaction incidence in combined group were significantly lower than those in the chemoradiotherapy group,and the rash with desquamation of the incidence was higher than chemo-therapy group (P<0.05).In combined group,1 year survival rate was significantly higher and the average survival time is longer than that in chemotherapy group (P<0.05).After the treatment,the survival quality of the combined group increased significantly than the chemotherapy group,and the rate of decreased quality of life is significantly reduced than chemoradiotherapy group (P<0.05 ).Con-clusion Whole brain radiotherapy combined with targeted therapy in patients with brain metastases of NSCLC has good therapeutic effect,which can reduce the adverse reaction and prolong the survival time of patients.
Keywords:Non-small cell lung cancer  Brain metastasis  Targeted therapy  Chemotherapy  Radiotherapy
本文献已被 万方数据 等数据库收录!
点击此处可从《安徽医药》浏览原始摘要信息
点击此处可从《安徽医药》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号